CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Shares of GRI Bio Inc. (NASDAQ:GRI) were trading at $6.28, up $3.08, or 96%, after the firm reported interim safety results from the ongoing phase IIa study testing GRI-0621 for idiopathic pulmonary ...

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...

Axsome Therapeutics Inc. investors can proceed with a proposed class action alleging the drugmaker misled them about a ...